You can not select more than 25 topics
Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
125 lines
2.6 KiB
125 lines
2.6 KiB
3 years ago
|
---
|
||
|
|
|
||
|
|
Alias: ["Valneva SE", "VLS.PA"]
|
||
|
|
Tag: ["Health", "Vaccine", "RareDesease"]
|
||
|
|
Date: 2021-08-17
|
||
|
|
DocType: "Investment"
|
||
|
|
Hierarchy: "NonRoot"
|
||
|
|
TimeStamp: 2021-08-17
|
||
|
|
location: [47.2329863,-1.6420352]
|
||
|
|
Investment:
|
||
|
|
Type: "Equity"
|
||
|
|
Style: "Growth"
|
||
|
|
Stage: "Scale-Up"
|
||
|
|
Ccy: EUR
|
||
|
|
Trading:
|
||
|
|
PDate: 2021-05-03
|
||
|
|
PPrice: 13.9
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
Parent:: [[Equity Investments|Equity Investment]]
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
```button
|
||
|
|
name Edit Investment parameters
|
||
|
|
type command
|
||
|
|
action MetaEdit: Run MetaEdit
|
||
|
|
id EditMetaData
|
||
|
|
```
|
||
|
|
^button-VLSInvEdit
|
||
|
|
|
||
|
|
```button
|
||
|
|
name Save
|
||
|
|
type command
|
||
|
|
action Save current file
|
||
|
|
id Save
|
||
|
|
```
|
||
|
|
^button-VLSInvSave
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
# Valneva
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
```ad-abstract
|
||
|
|
title: Summary
|
||
|
|
collapse: open
|
||
|
|
Valneva is a vaccine producer that came to the forelight when they disclosed that they were looking at a COVID19 vaccine. Their portfolio focusses on rare deseases that are not yet covered by a vaccine and use the mARN technology.
|
||
|
|
Current portfolio of studies include: COVID19, Lyme, Zika, Chikungunya, Chlostridiodes.
|
||
|
|
```
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
```toc
|
||
|
|
style: number
|
||
|
|
```
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
### Investment thesis
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
German-french pharmaceuticsl startup based in Nantes, it aims at disrupting the vaccine industry for deseases that have a low incidence and are therefore not extensively researched by big pharma labs.
|
||
|
|
At time of investment Valneva had achieved 90% efficiency on their 2nd round of trial for their COVID vaccine and were moving towards 3rd (and last) trial phase. Their mutation coverage spans a higher spectrum than competitors which makes this injection a good complement to current mainstream vaccines.
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
### Risk profile
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
<mark class="orange">High risk</mark>
|
||
|
|
Start-up with no proven vaccine: no recurring income and solely reliant on the success of their current research. High price volatility linked to expectation of success of trial phases of their fifferent vaccines currently being tested.
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
### News & corporate activity
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
#### Current pipeline
|
||
|
|
|
||
|
|
Currently, Vaneva's pipeline in a nutshell:
|
||
|
|
- [ ] <mark style="background:grey">Vaccine</mark>: Lyme desease
|
||
|
|
- [ ] <mark style="background:grey">Vaccine</mark>: Chikungunya
|
||
|
|
- [ ] <mark style="background:grey">Vaccine</mark>: Zika
|
||
|
|
- [ ] <mark style="background:grey">Vaccine</mark>: COVID19
|
||
|
|
- [ ] <mark style="background:grey">Distribution</mark>: Contract with the EU re COVID19
|
||
|
|
- [x] <mark style="background:grey">Distribution</mark>: Contract with the UK re COVID19
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
#### Innovation
|
||
|
|
|
||
|
|
Pipeline is inherently innovation.
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
### Further steps
|
||
|
|
|
||
|
|
 
|
||
|
|
|
||
|
|
Further steps are captured in the [[Equity Tasks|Equity task list]]
|
||
|
|
|
||
|
|
 
|
||
|
|
 
|